A detailed history of Black Rock Inc. transactions in Medicinova Inc stock. As of the latest transaction made, Black Rock Inc. holds 694,943 shares of MNOV stock, worth $1.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
694,943
Previous 695,420 0.07%
Holding current value
$1.51 Million
Previous $1.01 Million 0.79%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.28 - $1.57 $610 - $748
-477 Reduced 0.07%
694,943 $1 Million
Q1 2024

May 10, 2024

SELL
$1.28 - $1.65 $5,404 - $6,966
-4,222 Reduced 0.6%
695,420 $1.01 Million
Q4 2023

Feb 13, 2024

BUY
$1.38 - $2.06 $5,582 - $8,332
4,045 Added 0.58%
699,642 $1.05 Million
Q3 2023

Nov 13, 2023

SELL
$2.01 - $2.6 $71,901 - $93,007
-35,772 Reduced 4.89%
695,597 $1.45 Million
Q2 2023

Aug 11, 2023

BUY
$2.09 - $2.43 $34,459 - $40,065
16,488 Added 2.31%
731,369 $1.68 Million
Q1 2023

May 12, 2023

BUY
$1.95 - $2.54 $6,043 - $7,871
3,099 Added 0.44%
714,881 $1.54 Million
Q4 2022

Feb 13, 2023

BUY
$1.97 - $2.66 $2,220 - $2,997
1,127 Added 0.16%
711,782 $1.46 Million
Q3 2022

Nov 14, 2022

SELL
$2.1 - $2.6 $9,886 - $12,240
-4,708 Reduced 0.66%
710,655 $1.54 Million
Q2 2022

Aug 12, 2022

SELL
$2.31 - $3.14 $14,994 - $20,381
-6,491 Reduced 0.9%
715,363 $1.81 Million
Q1 2022

May 12, 2022

SELL
$2.19 - $2.81 $21,983 - $28,206
-10,038 Reduced 1.37%
721,854 $1.93 Million
Q4 2021

Feb 10, 2022

SELL
$2.61 - $4.42 $1.08 Million - $1.83 Million
-414,078 Reduced 36.13%
731,892 $1.96 Million
Q3 2021

Nov 09, 2021

BUY
$3.4 - $4.24 $61,363 - $76,523
18,048 Added 1.6%
1,145,970 $4.34 Million
Q2 2021

Aug 11, 2021

BUY
$3.76 - $5.14 $4.24 Million - $5.8 Million
1,127,922 New
1,127,922 $4.79 Million

Others Institutions Holding MNOV

About MEDICINOVA INC


  • Ticker MNOV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,046,200
  • Market Cap $106M
  • Description
  • MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...
More about MNOV
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.